Tag Archives: Syndax Pharmaceuticals

May, 2018

  • 31 May

    Syndax and Nektar Therapeutics Partner for Immuno-Oncology Clinical Trial

    WALTHAM, Mass. and SAN FRANCISCO, May 30, 2018 /PRNewswire/ — Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, and Nektar Therapeutics (Nasdaq: NKTR) today announced a non-exclusive, clinical collaboration to evaluate the safety and efficacy of Nektar’s NKTR-214, a CD122-biased agonist, …

January, 2018

January, 2016

March, 2015

  • 31 March

    Merck Teams Up with Syndax to Test Cancer Combination Regimen

    Merck has teamed up with privately-held Syndax Pharmaceuticals to test combining Syndax’s investigational epigenetic therapy, entinostat, with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), in cancer patients. The companies announced that they have entered into a clinical trial collaboration to evaluate the safety and efficacy of this novel combination regimen in patients …